🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The SEQUENCE Trial

RecruitingNAAges 18 Years - anyAllNorthwestern University
NCT06676956 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will randomize participants undergoing a bronchoscopic biopsy of a peripheral pulmonary nodule for their standard of care to receive robotic-assisted bronchoscopy (RaB) and then staging linear endobronchial ultrasounnd (EBUS) OR staging linear EBUS first, followed by RaB. The goal of this study is to set the standard for optimizing the sequence of bronchoscopic procedures in patients at risk for early-stage malignancy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Peripheral Pulmonary Nodule undergoing a robotic-assisted bronchoscopy Exclusion Criteria: * lymph nodes that are enlarged or PET avid on CT prior to procedure
💊

What it tests

  • Linear EBUS first
  • Robotic-assisted bronchoscopy first
📍

Where

5 sites
University of California, Davis
Sacramento, United States
Northwestern University
Chicago, United States
Johns Hopkins University
Baltimore, United States
University of Michigan
Ann Arbor, United States
University of North Carolina, Chapel Hill
Chapel Hill, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy